Dynavax Head and Neck Squamous Cell (HNSCC) Trial

CONDITION

Cancer

GENDER

Both males and females

AGE GROUP

From 18

and above

STATUS

Recruiting

This is a phase 2, open-label trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD 101 injections in combination with Keytruda (pembrolizumab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

This study is enrolling patient who have not yet received Keytruda or other anti-PD1 therapy and patients whose disease has progressed while receiving Keytruda or other anti-PD1 therapy.

CONTACT DETAILS

Phone Number: (08) 9446 8726

Email: info@affinityresearch.com.au

Location: 85 Monash Ave, Nedlands, Western Australia, Australia

Approved By: Bellberry Limited              

Clinical Trial Registry Link: Click Here